Capstone Wealth Management Group LLC Sells 34 Shares of Eli Lilly and Company (NYSE:LLY)

Capstone Wealth Management Group LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 422 shares of the company’s stock after selling 34 shares during the period. Capstone Wealth Management Group LLC’s holdings in Eli Lilly and Company were worth $326,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Fiduciary Financial Group LLC grew its position in Eli Lilly and Company by 89.2% during the 4th quarter. Fiduciary Financial Group LLC now owns 787 shares of the company’s stock worth $630,000 after acquiring an additional 371 shares during the last quarter. Mayfair Advisory Group LLC grew its position in Eli Lilly and Company by 4.4% during the 4th quarter. Mayfair Advisory Group LLC now owns 1,533 shares of the company’s stock worth $1,183,000 after acquiring an additional 64 shares during the last quarter. Affinity Capital Advisors LLC grew its position in Eli Lilly and Company by 0.4% during the 4th quarter. Affinity Capital Advisors LLC now owns 5,513 shares of the company’s stock worth $4,263,000 after acquiring an additional 23 shares during the last quarter. Quad Cities Investment Group LLC grew its position in Eli Lilly and Company by 5.6% during the 4th quarter. Quad Cities Investment Group LLC now owns 399 shares of the company’s stock worth $308,000 after acquiring an additional 21 shares during the last quarter. Finally, Biltmore Wealth Management LLC grew its position in Eli Lilly and Company by 26.8% during the 4th quarter. Biltmore Wealth Management LLC now owns 312 shares of the company’s stock worth $241,000 after acquiring an additional 66 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.2 %

LLY stock opened at $746.42 on Thursday. The stock’s 50 day simple moving average is $784.63 and its 200 day simple moving average is $857.48. Eli Lilly and Company has a fifty-two week low of $612.70 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $708.59 billion, a P/E ratio of 80.69, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 13.18 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 64.86%.

Eli Lilly and Company announced that its Board of Directors has approved a share repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Citigroup lifted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Finally, Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.